Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13).
Kim JW, Lee S, Kim HS, Choi YJ, Yoo J, Park KU, Kang SY, Park YH, Jung KH, Ahn JH, Oh HS, Choi IS, Kim HJ, Lee KH, Lee S, Seo JH, Park IH, Lee KE, Kim HY, Park KH. Kim JW, et al. Among authors: lee ke, lee kh, lee s. Cytokine. 2021 Jun;142:155487. doi: 10.1016/j.cyto.2021.155487. Epub 2021 Mar 23. Cytokine. 2021. PMID: 33770643
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.
Kim JW, Choi IS, Kim YJ, Lee KH, Lee KW, Kim TY, Han SW, Kim JH, Kim TY, Lee JS, Bang YJ, Im SA, Oh DY. Kim JW, et al. Among authors: lee js, lee kh, lee kw. Cancer Chemother Pharmacol. 2015 Jun;75(6):1175-82. doi: 10.1007/s00280-015-2732-9. Epub 2015 Apr 10. Cancer Chemother Pharmacol. 2015. PMID: 25860347 Clinical Trial.
Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane.
Koh HK, Shin KH, Kim K, Lee ES, Park IH, Lee KS, Ro J, Jung SY, Lee S, Kim SW, Kang HS, Chie EK, Han W, Noh DY, Lee KH, Im SA, Ha SW. Koh HK, et al. Among authors: lee ks, lee kh, lee es, lee s. Cancer Res Treat. 2016 Apr;48(2):483-90. doi: 10.4143/crt.2015.111. Epub 2015 Jun 5. Cancer Res Treat. 2016. PMID: 26044160 Free PMC article.
Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea.
Lee S, Park IH, Park S, Sohn J, Jeong J, Ahn SG, Lee IJ, Lee HK, Lee SA, Park W, Lee KH, Kim SW, Han SA, Jung KH, Son BH. Lee S, et al. Among authors: lee kh, lee sa, lee ij, lee hk. J Breast Cancer. 2017 Sep;20(3):228-233. doi: 10.4048/jbc.2017.20.3.228. Epub 2017 Sep 22. J Breast Cancer. 2017. PMID: 28970847 Free PMC article.
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: lee sj, lee ks, lee kh. Eur J Cancer. 2017 Nov;86:385-393. doi: 10.1016/j.ejca.2017.10.002. Epub 2017 Nov 5. Eur J Cancer. 2017. PMID: 29100193 Clinical Trial.
9,762 results